20,964 results match your criteria Alcoholic Fatty Liver


Astaxanthin attenuates hepatic damages and mitochondrial dysfunction in nonalcoholic fatty liver disease by up-regulating the FGF21/PGC-1α pathway.

Br J Pharmacol 2020 May 22. Epub 2020 May 22.

Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.

Background And Purpose: Non-alcoholic fatty liver disease (NAFLD) is considered to be one of the most common chronic liver diseases across worldwide. Astaxanthin (Ax) is a type of carotenoid,and beneficial effects of Ax,including anti-oxidative, anti-inflammatory, and anti-tumor activity, have been identified. The present study aimed to elucidate the protective effect of Ax against NAFLD and its underlying mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.15099DOI Listing

Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis.

Semin Arthritis Rheum 2020 May 11;50(4):544-548. Epub 2020 May 11.

Department of Rheumatology, CHRU Besançon - France; EA 4266 "Pathogens and inflammation, EPILAB", Université Bourgogne - Franche Comte, UFR SMP, Besançon, France.

The management of inflammatory rheumatic diseases has substantially changed in recent years, as has the profile of patients. The advent of biotherapies has been a revolution in rheumatology and the impact of co-morbidities in the management of these patients is now becoming increasingly important. Metabolic syndrome (MetS) is one of the most frequent comorbidities, and hepatic complications of MetS are not uncommon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2020.03.013DOI Listing

Adipose tissue-liver crosstalk during pathologic changes caused by vinyl chloride metabolites in mice.

Toxicol Appl Pharmacol 2020 May 20:115068. Epub 2020 May 20.

Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, United States of America; Pittsburgh Liver Research Center, Pittsburgh, PA 15213, United States of America. Electronic address:

Volatile organic compounds (VOCs), such as vinyl chloride (VC), can be directly toxic at high concentrations. However, we have shown that 'nontoxic' exposures to VC and its metabolite chloroethanol (CE) enhances experimental non-alcoholic fatty liver disease (NAFLD), suggesting an unpredicted interaction. Importantly, VOC exposure has been identified as a potential risk factor for the development of obesity and its sequelae in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.taap.2020.115068DOI Listing

Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study.

Sci Rep 2020 May 22;10(1):8496. Epub 2020 May 22.

Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil.

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease with several degrees of histological features which may progress to cirrhosis. Obesity is an important risk factor and although NAFLD has no specific pharmacological treatment, bariatric surgery has been associated with NAFLD regression in severely obese patients. However, few longitudinal histological studies support this finding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65556-2DOI Listing

Hepatic lipid droplet homeostasis and fatty liver disease.

Semin Cell Dev Biol 2020 May 19. Epub 2020 May 19.

Institute for Diabetes and Obesity, Helmholtz Center Munich, 85764 Neuherberg, Germany; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany. Electronic address:

In cells, lipids are stored in lipid droplets, dynamic organelles that adapt their size, abundance, lipid and protein composition and organelle interactions to metabolic changes. Lipid droplet accumulation in the liver is the hallmark of non-alcoholic fatty liver disease (NAFLD). Due to the prevalence of obesity, the strongest risk factor for steatosis, NAFLD and its associated complications are currently affecting more than 1 billion people worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2020.04.011DOI Listing

Relationship between circulating miR-132 and non-alcoholic fatty liver disease in a Chinese population.

Hereditas 2020 May 22;157(1):22. Epub 2020 May 22.

Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.

Background: Non-invasive diagnostic markers are of great importance for early screening nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) play significant roles in many metabolic disease, including NAFLD. Therefore, this study focusd on a Chinese population to explore the possible correlation between circulating miR-132 and NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41065-020-00136-yDOI Listing

Bromelain Confers Protection against the Non-Alcoholic Fatty Liver Disease in Male C57bl/6 Mice.

Nutrients 2020 May 18;12(5). Epub 2020 May 18.

Graduate Institute and Department of Physiology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan.

We aimed to investigate the effect of bromelain, the extract from stems of pineapples on the high-fat diet (HFD)-induced deregulation of hepatic lipid metabolism and non-alcoholic fatty liver disease (NAFLD), and its underlying mechanism in mice. Mice were daily administrated with HFD with or without bromelain (20 mg/kg) for 12 weeks, and we found that bromelain decreased the HFD-induced increase in body weight by ~30%, organ weight by ~20% in liver weight and ~40% in white adipose tissue weight. Additionally, bromelain attenuated HFD-induced hyperlipidemia by decreasing the serum level of total cholesterol by ~15% and triglycerides level by ~25% in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12051458DOI Listing

Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population.

Int J Environ Res Public Health 2020 May 18;17(10). Epub 2020 May 18.

Internal Medicine Department, Regional University Hospital of Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.

The aim of this study was to analyze the utility of liver function tests (LFT) and fatty liver index (FLI), a surrogate marker of non-alcoholic fatty liver disease, in the categorization of metabolic phenotypes in a Mediterranean population. A cross-sectional study was performed on a random representative sample of 2233 adults assigned to a health center in Málaga, Spain. The metabolic phenotypes were determined based on body mass index (BMI) categorization and the presence or absence of two or more cardiometabolic abnormalities (high blood pressure, low high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, pre-diabetes) or type 2 diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph17103518DOI Listing

From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years.

Diabetes Metab Syndr 2020 May 13;14(4):695-696. Epub 2020 May 13.

Fortis CDOC Hospital for Diabetes and Allied Sciences, New Delhi, India; National Diabetes Obesity and Cholesterol Foundation (NDOC) and Diabetes Foundation, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dsx.2020.05.019DOI Listing

Gastric banding-associated weight loss diminishes hepatic Tsukushi expression.

Cytokine 2020 May 19;133:155114. Epub 2020 May 19.

Department of Internal Medicine I, Gastroenterology, Hepatology and Endocrinology, Medical University of Innsbruck, Innsbruck, Austria.

Obesity has emerged as a substantial global healthcare issue that is frequently associated with insulin resistance and non-alcoholic fatty liver disease (NAFLD). Tsukushi (TSK), a liver-derived molecule, was recently identified as a major driver of NAFLD. Laparoscopic adjustable gastric banding (LAGB) has proven effective in reducing body weight and improving NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2020.155114DOI Listing

Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

J Nephrol 2020 May 21. Epub 2020 May 21.

Dialysis Unit, School of Medicine, IIS-Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Avd. Reyes Católicos 2, 28040, Madrid, Spain.

The most common cause of liver disease worldwide is now non-alcoholic fatty liver disease (NAFLD). NAFLD refers to a spectrum of disease ranging from steatosis to non-alcoholic steatohepatitis, causing cirrhosis, and ultimately hepatocellular carcinoma. However, the impact of NAFLD is not limited to the liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40620-020-00751-yDOI Listing

Theaphenon E prevents fatty liver disease and increases CD4+ T cell survival in mice fed a high-fat diet.

Clin Nutr 2020 May 4. Epub 2020 May 4.

Department of Biochemistry & Molecular Biology, Georgetown University Medical Center, Washington, DC 20057, USA; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA. Electronic address:

Background & Aims: Obesity is a major cause of non-alcoholic fatty liver disease (NAFLD). NAFLD is an epidemic affecting nearly 34% of the adult population in the US. As a chronic inflammatory disease, NAFLD influences the immune system by dysregulating T-cell activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clnu.2020.04.033DOI Listing

Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor.

Life Sci 2020 May 10:117776. Epub 2020 May 10.

Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Medical University, Chongqing 400016, China. Electronic address:

Aims: Rg1 is the most active component of traditional Chinese medicine ginseng, having anti-aging and anti-oxidative stress feature in multiple organs. Cellular senescence of hepatocytes is involved in the progression of a wide spectrum of chronic liver diseases. In this study, we investigated the potential benefits and mechanism of action of Rg1 on aging-driven chronic liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2020.117776DOI Listing

Non-alcoholic fatty liver disease increases the prevalence of maintenance haemodialysis in patients with chronic kidney disease.

Authors:
Y C Lu C Y Hsu

Bratisl Lek Listy 2020 ;121(5):348-351

Aim: To investigate the association between non-alcoholic fatty liver disease (NAFLD) and incidence of maintenance haemodialysis in patients with chronic kidney disease (CKD).

Methods: We enrolled patients diagnosed with CKD between 2001 and 2007. The patients were categorized into two groups based on abdominal ultrasound finding, namely those with NAFLD and those without NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/BLL_2020_055DOI Listing
January 2020

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.

Curr Pharm Des 2020 May 21. Epub 2020 May 21.

Sezione di Gastroenterologia e Epatologia, PROMISE, university of Palermo. Italy.

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of liver disease worldwide, involving about 25% of people. NAFLD embraces a large spectrum of patological conditions, from simple steatosis, to non-acoholic steatohepatis (NASH), cirrhosis and its complications, including hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in asymptomatic way, until advanced fibrosis appears. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612826666200521133307DOI Listing

Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.

High Blood Press Cardiovasc Prev 2020 May 20. Epub 2020 May 20.

Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, c/o 2a Medicina Spedali Civili di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy.

Introduction: The study aimed to investigate, in patients with primary non-alcoholic fatty liver disease (NAFLD), the presence of possible relationships between the degree of steatosis or fibrosis and the individual cardiovascular risk and possibly whether a difference between those various methods exists.

Methods: Thirty-four adult patients with primary NAFLD were included in this study. Clinical evaluation included an ultrasonographic examination for the determination of the severity of steatosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40292-020-00389-8DOI Listing

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.

JHEP Rep 2020 Jun 6;2(3):100099. Epub 2020 Mar 6.

Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK & Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.

Background & Aims: Non-alcoholic steatohepatitis (NASH) is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. The burden of NASH-related cirrhosis from the patient perspective remains poorly understood. Herein, we aimed to identify the burden of disease and HRQoL impairment among patients with NASH-related compensated cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhepr.2020.100099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229498PMC

MiR-155 and MiR-665 Role as Potential Non-invasive Biomarkers for Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.

J Transl Int Med 2020 Mar 9;8(1):32-40. Epub 2020 May 9.

Clinical Oncology Department, Kasralainy, Cairo University, Cairo, Egypt.

Background And Objectives: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer associated death globally. Serum micro RNAs are full of potential as noninvasive biomarkers. Here, we aim to assess the performance of serum MicroRNA-155 and MicroRNA-665 as diagnostic biomarker for HCC comparing to AFP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/jtim-2020-0006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227164PMC

Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics.

World J Gastrointest Pathophysiol 2020 May;11(3):57-63

Department of Clinical and Experimental Medicine, the School of Medicine of the University of Catania, Catania 95125, Italy.

Atherosclerosis (ATH) and non-alcoholic fatty liver disease (NAFLD) are medical conditions that straddle a communal epidemiology, underlying mechanism and a clinical syndrome that has protean manifestations, touching every organ in the body. These twin partners, ATH and NAFLD, are seemingly straightforward and relatively simple topics when considered alone, but their interdependence calls for more thought. The study of the mutual relationship of NAFLD and ATH should involve big data analytics approaches, given that they encompass a constellation of diseases and are related to several recognized risk factors and health determinants and calls to an explicit theory of change, to justify intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4291/wjgp.v11.i3.57DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226912PMC

The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study.

Clin Res Hepatol Gastroenterol 2020 May 17. Epub 2020 May 17.

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.

Background And Aims: Visceral adiposity index (VAI), calculated with body mass index, high-density lipoprotein cholesterol, triglyceride and waist circumference, has been proposed as a marker of visceral fat accumulation and dysfunction.

Methods: The impact of VAI on incident nonalcoholic fatty liver disease (NAFLD) in a historical cohort study of 8399 (3773 men and 4626 women) participants. NAFLD was defined as having fatty liver diagnosed by abdominal ultrasonography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2019.04.002DOI Listing

Hypoxia-inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36.

Liver Int 2020 May 20. Epub 2020 May 20.

Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, 28009, Madrid, Spain.

Background & Aims: Molecular mechanisms by which hypoxia might contribute to hepatosteatosis, the earliest stage in non-alcoholic fatty liver disease (NAFLD) pathogenesis, remain still to be elucidated. We aimed to assess the impact of hypoxia-inducible factor 2α (HIF2α) on the fatty acid translocase CD36 expression and function in vivo and in vitro.

Methods: CD36 expression and intracellular lipid content were determined in hypoxic hepatocytes, and in hypoxic CD36- or HIF2α -silenced human liver cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14519DOI Listing

Cholesteryl ester storage disease of clinical and genetic characterisation: A case report and review of literature.

World J Clin Cases 2020 May;8(9):1642-1650

Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre 2650, Denmark.

Background: Cholesteryl ester storage disease (CESD) is a rare genetic disease. Its symptoms and severity are highly variable. CESD is a systemic disease that can lead to the accumulation of fat and inflammation in the liver, as well as gastrointestinal and cardiovascular disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v8.i9.1642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211528PMC

Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran: A Population-Based Study.

Diabetes Metab Syndr Obes 2020 1;13:1449-1458. Epub 2020 May 1.

Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Aim: Gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS) are common problems. The aim of this study was to investigate the association between NAFLD, MetS and its components with GSD.

Materials and methods: This cross-sectional study was conducted as a part of the Kavar Cohort Study (KCS) affiliated to Shiraz University of Medical Sciences, Shiraz, Iran between January 2012 and January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DMSO.S246949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200259PMC

Different Potent Glucocorticoids, Different Routes of Exposure but The Same Result: Iatrogenic Cushing's syndrome and Adrenal Insufficiency.

Authors:
Ayla Güven

J Clin Res Pediatr Endocrinol 2020 May 20. Epub 2020 May 20.

Health Science University Medical Faculty, Zeynep Kamil Women and Children Hospital, Pediatric Endocrinology Clinic.

Objectives: Potent glucocorticoids (GC) cause iatrogenic Cushing Syndrome (ICS) due to suppression of hypothalamo-hypophyseal-adrenal (HPA) axis and later even adrenal insufficiency (AI). The aim of this study is to review the clinical and laboratory findings of patients with ICS and to demonstrate other serious side effects.

Methods: The possibility of AI was investigated by low-dose ACTH test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/jcrpe.galenos.2020.2019.0220DOI Listing

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.

Diabetes Metab J 2020 May 11. Epub 2020 May 11.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-proton density fat fraction are recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4093/dmj.2020.0010DOI Listing

Chia (Salvia hispanica)-supplemented diet ameliorates non-alcoholic fatty liver disease and its metabolic abnormalities in humans.

Lipids Health Dis 2020 May 19;19(1):96. Epub 2020 May 19.

Departamento de Endocrinología, Juan Badiano 1, Col. Sección XVI, Tlalpan, Mexico City, Mexico.

Background: Non-alcoholic fatty liver disease (NAFLD) is a public health problem lacking an approved pharmacological treatment. Omega-3 fatty acids have shown to reverse NAFLD. Chia is a seed rich in α-linolenic acid (ALA), antioxidants, and fiber; therefore, it could be useful to treat NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12944-020-01283-xDOI Listing
May 2020
2.219 Impact Factor

Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway.

BMC Immunol 2020 May 19;21(1):28. Epub 2020 May 19.

Department of Gastroenterology, Tongde Hospital of Zhejiang Province, 234 Gucui Road, Zhejiang, 310012, Hangzhou, China.

Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease worldwide. Recent studies have shown that the Angptl2 pathway mediated hepatic inflammatory response plays an important role in the progression of nonalcoholic fatty liver disease. Our study investigated the possible molecular mechanisms of berberine (BBR) in the treatment of the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD via the Angptl2 pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12865-020-00358-9DOI Listing

Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH.

Cells 2020 May 16;9(5). Epub 2020 May 16.

Department of Experimental and Clinical Medicine and Center of Excellence "DENOthe", University of Florence, 50134 Florence, Italy.

In non-alcoholic steatohepatitis (NASH), many lines of investigation have reported a dysregulation in lipid homeostasis, leading to intrahepatic lipid accumulation. Recently, the role of dysfunctional sphingolipid metabolism has also been proposed. Human and animal models of NASH have been associated with elevated levels of long chain ceramides and pro-apoptotic sphingolipid metabolites, implicated in regulating fatty acid oxidation and inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9051237DOI Listing

The Protective Effect of Cynara Cardunculus Extract in Diet-Induced NAFLD: Involvement of OCTN1 and OCTN2 Transporter Subfamily.

Nutrients 2020 May 15;12(5). Epub 2020 May 15.

Institute of Research for Food Safety & Health, Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.

and insulin-resistance are often associated with Non-Alcoholic Fatty Liver Disease (NAFLD) thereby representing a true issue worldwide due to increased risk of developing cardiovascular and systemic disorders. Although clear evidence suggests that circulating fatty acids contribute to pathophysiological mechanisms underlying NAFLD and hyperlipidemia, further studies are required to better identify potential beneficial approaches for counteracting such a disease. Recently, several artichoke extracts have been used for both reducing hyperlipidemia, insulin-resistance and NAFLD, though the mechanism is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12051435DOI Listing

Hepatic steatosis among people living with HIV in Southern Brazil: prevalence and risk factors.

Sci Rep 2020 May 19;10(1):8282. Epub 2020 May 19.

Science Health Institute, Centro Universitário Ritter dos Reis, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65133-7DOI Listing

The liver in times of COVID-19: What hepatologists should know.

Ann Hepatol 2020 May 18. Epub 2020 May 18.

Latin American Liver Research, Educational and Awareness Network (LALREAN) Pilar, Provincia de Buenos Aires Argentina, Argentina.

The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding to the how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations to be considered in liver transplant patients or those having hepatocellular carcinoma or are under immunosuppressive therapy are being matter of analysis as information is being generated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233236PMC

Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply.

Aliment Pharmacol Ther 2020 Jun;51(11):1200-1201

Department of Gastroenterology and Hepatology, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15724DOI Listing

Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world?

Aliment Pharmacol Ther 2020 Jun;51(11):1199-1200

NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15714DOI Listing

Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.

Adv Exp Med Biol 2020 May 19. Epub 2020 May 19.

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading liver disease globally. NAFLD patients can have a progressive phenotype, non-alcoholic steatohepatitis (NASH) that could lead to cirrhosis, liver failure and cancer. There is a close bi-directional relationship between NAFLD and type 2 diabetes mellitus (T2DM); NAFLD increases the risk for T2DM and its complications whereas T2DM increases the severity of NAFLD and its complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/5584_2020_532DOI Listing

Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".

J Hepatol 2020 May 15. Epub 2020 May 15.

Service d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, UPRES 3859, SFR 4208, Université d'Angers, Angers, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.04.020DOI Listing

A Diet Rich in Saturated Fat and Cholesterol Aggravates the Effect of Bacterial Lipopolysaccharide on Alveolar Bone Loss in a Rabbit Model of Periodontal Disease.

Nutrients 2020 May 14;12(5). Epub 2020 May 14.

Institute of Nutrition and Food Technology "José Mataix Verdú", Department of Physiology, Biomedical Research Center, University of Granada, Avda del Conocimiento sn, Armilla, 18016 Granada, Spain.

Increasing evidence connects periodontitis with a variety of systemic diseases, including metabolic syndrome, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). The proposal of this study was to evaluate the role of diets rich in saturated fat and cholesterol in some aspects of periodontal diseases in a lipopolysaccharide (LPS)-induced model of periodontal disease in rabbits and to assess the influence of a periodontal intervention on hyperlipidemia, atherosclerosis, and NAFLD progression to non-alcoholic steatohepatitis. Male rabbits were maintained on a commercial standard diet or a diet rich in saturated fat (3% lard /) and cholesterol (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12051405DOI Listing

Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases.

Transl Lung Cancer Res 2020 Apr;9(2):316-324

Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.

Background: Recent studies have suggested obesity could contribute to improved outcomes of immune checkpoint inhibitor (ICI)-based treatment. Non-alcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease, is also obesity-related, but its association with the efficacy of ICI-based treatment has not yet been reported.

Methods: We retrospectively reviewed the medical records of advanced non-small cell lung cancer (NSCLC) patients treated at Shanghai Pulmonary Hospital between June 2015 and June 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2020.04.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225134PMC

Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease.

Biochem Genet 2020 May 17. Epub 2020 May 17.

College of Pharmacy, Harbin Medical University, Harbin, 150001, People's Republic of China.

Non-alcoholic fatty liver disease (NAFLD) have a high prevalence in humans in the past two decades. Here, we elucidated the functions of miR-30a-3p in the development of NAFLD and identified its potential targets. HepG-2 cells and NAFLD patients' blood samples were used in our study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10528-020-09971-0DOI Listing

Prevalence and Risk Factors of Moderate to Severe Hepatic Steatosis in HIV Infection: The Copenhagen Co-Morbidity Liver Study.

J Infect Dis 2020 May 16. Epub 2020 May 16.

Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Hvidovre.

Background: People living with HIV (PWH) may be at risk of non-alcoholic fatty liver disease (NAFLD). We compared the prevalence of moderate-to-severe hepatic steatosis (M-HS) in PWH with HIV-uninfected controls and determined risk factors for M-HS in PWH.

Methods: The Copenhagen Co-Morbidity in HIV infection Study included 453 participants and the Copenhagen General Population Study 765 participants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiaa246DOI Listing

GSK-3 in liver diseases: Friend or foe?

Biochim Biophys Acta Mol Cell Res 2020 May 14:118743. Epub 2020 May 14.

Institute for Biomedical Research and Innovation, National Research Council (CNR), Palermo, Italy. Electronic address:

Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbamcr.2020.118743DOI Listing

Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein.

Chem Biol Interact 2020 May 14;325:109131. Epub 2020 May 14.

Louisiana State University Health Sciences Center, New Orleans, USA.

We have previously demonstrated promotion of diethylnitrosamine (DEN) initiated liver tumorigenesis after feeding diets high in fat or ethanol (EtOH) to male mice. This was accompanied by hepatic induction of the proto-oncogene PIKE (Agap2). Switch of dietary protein from casein to soy protein isolate (SPI) significantly reduced tumor formation in these models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2020.109131DOI Listing

The effect of sleep on gastrointestinal functioning in common digestive diseases.

Lancet Gastroenterol Hepatol 2020 Jun;5(6):616-624

Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address:

Sleep quality and sleep disorders affect symptom manifestation and the pathogenesis of digestive diseases. Sleep is largely regulated by the light-dark cycle and associated circadian rhythms. These occurrences are closely regulated through several mechanisms with direct effects on the gastrointestinal tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30412-1DOI Listing

Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment.

Clin Med (Lond) 2020 May;20(3):313-318

UCL Institute for Liver and Digestive Health, London, UK

Non-alcoholic fatty liver disease (NAFLD) accounts for 10-15% of orthotopic liver transplants (OLTs) in the UK. Index presentations with cirrhotic decompensation represent missed opportunities for preventive treatment leaving OLT or palliation as the only options.We retrospectively reviewed patient records for all NAFLD patients undergoing assessment for OLT between January 2003 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7861/clinmed.2019-0250DOI Listing

Overexpression of miR-142-5p inhibits the progression of nonalcoholic steatohepatitis by targeting TSLP and inhibiting JAK-STAT signaling pathway.

Aging (Albany NY) 2020 May 15;12. Epub 2020 May 15.

Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan, China.

This study aimed to figure out the underlying mechanism of miR-142-5p in the non-alcoholic steatohepatitis (NASH). Bioinformatics, luciferase assay and Western blot were performed. The NASH mouse model was established through feeding a high fat diet (HFD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103172DOI Listing
May 2020
6.432 Impact Factor

Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health.

Lancet Gastroenterol Hepatol 2020 May 12. Epub 2020 May 12.

Liver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(20)30090-XDOI Listing

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Lancet Gastroenterol Hepatol 2020 May 12. Epub 2020 May 12.

Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. Electronic address:

Background: Although non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, it is increasingly being identified in non-obese individuals. We aimed to characterise the prevalence, incidence, and long-term outcomes of non-obese or lean NAFLD at a global level.

Methods: For this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and the Cochrane Library from inception to May 1, 2019, for relevant original research articles without any language restrictions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(20)30077-7DOI Listing

Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue.

Front Endocrinol (Lausanne) 2020 29;11:259. Epub 2020 Apr 29.

Laboratory of Myeloid Cell Heterogeneity and Function, VIB-UGent Center for Inflammation Research, Ghent, Belgium.

The increasing prevalence of obesity is accompanied by a rising incidence in metabolic syndrome and related pathologies such as non-alcoholic fatty liver disease. Macrophages are hypothesized to play central roles in these diseases, through their role as inflammatory mediators and as such are thought to be potential targets for future therapies. Recently, single cell technologies have revealed significant heterogeneity within the macrophage pool in both liver and adipose tissue in obesity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2020.00259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201095PMC

Hepatic steatosis induced in C57BL/6 mice by a non-ß oxidizable fatty acid analogue is associated with reduced plasma kynurenine metabolites and a modified hepatic NAD/NADH ratio.

Lipids Health Dis 2020 May 14;19(1):94. Epub 2020 May 14.

Department of Clinical Science, University of Bergen, Bergen, Norway.

Background: Non-alcoholic fatty liver disease is often associated with obesity, insulin resistance, dyslipidemia, and the metabolic syndrome in addition to mitochondrial dysfunction and nicotinamide adenine dinucleotide (NAD) deficiency. The aim of this study was to investigate how inhibition of mitochondrial fatty acid oxidation using the compound tetradecylthiopropionic acid (TTP) would affect hepatic triacylglycerol level and plasma levels of kynurenine (Kyn) metabolites and nicotinamide.

Methods: 12 C57BL/6 mice were fed a control diet, or an intervention diet supplemented with 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12944-020-01271-1DOI Listing

HLA-DQB1*06 reduces fibrosis score in patients with non-alcoholic fatty liver disease.

Hepatol Res 2020 May 14. Epub 2020 May 14.

Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Aim: Human leukocyte antigen (HLA) regions were highlighted as important genetic markers for various liver diseases by hepatology-related genome-wide association studies. Replication studies in non-alcoholic fatty liver disease (NAFLD) are limited and none has investigated the association of HLA alleles with non-alcoholic steatohepatitis (NASH) and other histological characteristics. In the current study, we examined the association of HLA-DQA1 and HLA-DQB1 alleles with NAFLD spectrum and its histological characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.13525DOI Listing

Objectively measured sedentary time, physical activity, and liver enzyme elevations in US Hispanics/Latinos.

Liver Int 2020 May 14. Epub 2020 May 14.

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Background & Aims: Sedentariness and physical inactiveness are associated with deleterious health outcomes, but their associations with liver enzyme elevations remain uncertain.

Methods: In 10 385 US Hispanics/Latinos from the Hispanic Community Health Study/Study of Latinos, we examined associations of sedentary time and moderate-to-vigorous physical activity (MVPA) measured by accelerometers with liver enzyme elevations. Elevated alanine aminotransferase (ALT), aspartate aminotransferase, and γ-glutamyltransferase (GGT) were defined as the highest sex-specific deciles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14514DOI Listing